

Astrid Maria Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9025949/publications.pdf>

Version: 2024-02-01

68
papers

2,853
citations

136940

32
h-index

182417

51
g-index

72
all docs

72
docs citations

72
times ranked

3389
citing authors

#	ARTICLE	IF	CITATIONS
1	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. <i>Brain</i> , 2008, 131, 690-705.	7.6	292
2	Pathological gambling in Parkinson disease is reduced by amantadine. <i>Annals of Neurology</i> , 2010, 68, 400-404.	5.3	201
3	Reversible parkinsonism induced by prolonged treatment with valproate. <i>Journal of Neurology</i> , 1998, 245, 794-796.	3.6	109
4	Botulinum toxin treatment of lateral axial dystonia in parkinsonism. <i>Movement Disorders</i> , 2007, 22, 2097-2103.	3.9	107
5	Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 434-445.	3.1	99
6	Default network is not hypoactive in dementia with fluctuating cognition: an Alzheimer disease/dementia with Lewy bodies comparison. <i>Neurobiology of Aging</i> , 2013, 34, 1148-1158.	3.1	92
7	Acute akinesia in Parkinson disease. <i>Neurology</i> , 2005, 64, 1162-1169.	1.1	91
8	The Characterization of Regulatory T-Cell Profiles in Alzheimer's Disease and Multiple Sclerosis. <i>Scientific Reports</i> , 2019, 9, 8788.	3.3	90
9	Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. <i>Neurology</i> , 2010, 74, 1598-1606.	1.1	88
10	Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 Months. <i>Clinical Neuropharmacology</i> , 2001, 24, 31-42.	0.7	77
11	Thalamic Involvement in Fluctuating Cognition in Dementia with Lewy Bodies: Magnetic Resonance Evidences. <i>Cerebral Cortex</i> , 2015, 25, 3682-3689.	2.9	73
12	Pisa syndrome in Parkinson disease. <i>Neurology</i> , 2015, 85, 1769-1779.	1.1	72
13	An expert opinion on safinamide in Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1115-1125.	4.1	71
14	The Effects of a Cholinesterase Inhibitor Are Prominent in Patients With Fluctuating Cognition: A Part 3 Study of the Main Mechanism of Cholinesterase Inhibitors in Dementia. <i>Clinical Neuropharmacology</i> , 2003, 26, 239-251.	0.7	70
15	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.	3.9	70
16	Structural Alteration of the Dorsal Visual Network in DLB Patients with Visual Hallucinations: A Cortical Thickness MRI Study. <i>PLoS ONE</i> , 2014, 9, e86624.	2.5	53
17	Atrophy of hippocampal subfields and adjacent extrahippocampal structures in dementia with Lewy bodies and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 40, 103-109.	3.1	52
18	Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. <i>Frontiers in Neurology</i> , 2021, 12, 644317.	2.4	51

#	ARTICLE	IF	CITATIONS
19	Donepezil Versus Vitamin E in Alzheimer's Disease Part 2: Mild Versus Moderateâ€“Severe Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 207-215.	0.7	50
20	Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism. <i>Neuromuscular Disorders</i> , 2008, 18, 460-464.	0.6	49
21	Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S233-S236.	2.2	46
22	Effects of dexamipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. <i>Brain Research</i> , 2012, 1446, 1-11.	2.2	46
23	Autoscopic phenomena: case report and review of literature. <i>Behavioral and Brain Functions</i> , 2011, 7, 2.	3.3	45
24	Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 981-986.	2.2	45
25	Dopa-responsive pseudo-orthostatic tremor in parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1652-1656.	3.9	44
26	Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. <i>Journal of the Neurological Sciences</i> , 2011, 310, 166-171.	0.6	43
27	Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 925-936.	2.8	43
28	A Stage-Based Approach to Therapy in Parkinsonâ€™s Disease. <i>Biomolecules</i> , 2019, 9, 388.	4.0	41
29	Structural Connectivity is Differently Altered in Dementia with Lewy Body and Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 208.	3.4	38
30	Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. <i>Cortex</i> , 2014, 59, 12-21.	2.4	37
31	Fluctuating cognition and different cognitive and behavioural profiles in Parkinsonâ€™s disease with dementia: comparison of dementia with Lewy bodies and Alzheimerâ€™s disease. <i>Journal of Neurology</i> , 2010, 257, 1004-1011.	3.6	36
32	New approaches to understanding hallucinations in Parkinsonâ€™s disease: phenomenology and possible origins. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1731-1750.	2.8	35
33	Akinetic crisis, acute akinesia, neuroleptic malignantâ€“like syndrome, Parkinsonismâ€“hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. <i>Movement Disorders</i> , 2005, 20, 1671-1671.	3.9	33
34	HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 337-340.	3.9	30
35	Paradoxical kinesia in parkinsonian patients surviving earthquake. <i>Movement Disorders</i> , 2010, 25, 1302-1304.	3.9	29
36	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2006, 253, 1633-1639.	3.6	26

#	ARTICLE	IF	CITATIONS
37	Delayed blink reflex in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1137-1139.	1.9	26
38	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013, 260, 1731-1742.	3.6	23
39	Somatization in Parkinson's Disease: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 18-26.	4.8	23
40	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 703-705.	2.2	22
41	Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2599-2611.	3.1	22
42	Source model and scalp topography of pattern reversal visual evoked potentials to altitudinal stimuli suggest that infoldings of calcarine fissure are not part of VEP generators. <i>Brain Topography</i> , 1995, 7, 217-231.	1.8	20
43	Severe worsening of parkinsonism in Lewy body dementia due to donepezil. <i>Neurology</i> , 2003, 61, 1452-1452.	1.1	20
44	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1093.	2.2	20
45	Visual Evoked Potentials Generator Model Derived from Different Spatial Frequency Stimuli of Visual Field Regions and Magnetic Resonance Imaging Coordinates of V1, V2, V3 Areas in Man. <i>International Journal of Neuroscience</i> , 1995, 83, 213-239.	1.6	18
46	Morphological and Metabolic Changes in the Nigro-Striatal Pathway of Synthetic Proteasome Inhibitor (PSI)-Treated Rats: A MRI and MRS Study. <i>PLoS ONE</i> , 2013, 8, e56501.	2.5	16
47	Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 1095-1097.	2.7	14
48	Nonepileptic seizures under levetiracetam therapy: a case report of forced normalization process. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 959.	2.2	14
49	One Further Case of Pancytopenia Induced by Olanzapine in a Parkinson's Disease Patient. <i>European Neurology</i> , 2001, 45, 56-57.	1.4	13
50	Psychosis in parkinsonism: an unorthodox approach. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1313-1330.	2.2	13
51	Task-specific lower lip dystonia due to mantra recitation. <i>Movement Disorders</i> , 2007, 22, 439-440.	3.9	12
52	Acetazolamide-responsive periodic ataxia induced by amiodarone. <i>Movement Disorders</i> , 1999, 14, 379-381.	3.9	10
53	Responsiveness of dysphagia to acute l-Dopa challenge in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2014, 261, 441-442.	3.6	10
54	Functional neurological disorder and somatic symptom disorder in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120017.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Delayed Blink Reflex in Dementia With Lewy Bodies Is Sensitive to Cholinergic Modulation. <i>Clinical Neuropharmacology</i> , 2008, 31, 231-237.	0.7	9
56	Cortical Activation During Levitation and Tentacular Movements of Corticobasal Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1977.	1.0	9
57	Visual Hallucinations as Incidental Negative Effects of Virtual Reality on Parkinson's Disease Patients: A Link with Neurodegeneration?. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	1.1	9
58	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2840-2852.	3.9	8
59	Optic Neuritis with Residual Tunnel Vision in Perchloroethylene Toxicity. <i>Journal of Toxicology: Clinical Toxicology</i> , 1998, 36, 603-607.	1.5	6
60	Eyelid retraction in dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1542-1544.	3.6	5
61	Electrophysiological indices of interference resolution covary with individual fluid intelligence: investigating reactive control processes in a 3-back working memory task. <i>NeuroImage</i> , 2014, 93, 146-153.	4.2	4
62	A Critical Review of Alien Limb-Related Phenomena and Implications for Functional Magnetic Resonance Imaging Studies. <i>Frontiers in Neurology</i> , 2021, 12, 661130.	2.4	4
63	Somatoform Disorders in Parkinson's Disease and Dementia with Lewy Bodies Evidence Underlying Psychotic Traits. <i>Advances in Biological Psychiatry</i> , 2012, , 125-132.	0.2	3
64	Optic Neuritis with Residual Tunnel Vision in Perchloroethylene Toxicity. <i>European Neurology</i> , 1999, 41, 51-53.	1.4	2
65	Amantadine and antiglutamatergic drugs in the management of Parkinson's disease. , 0, , 13-22.		2
66	Sporadic acetazolamide-responsive episodic ataxia. <i>Movement Disorders</i> , 1999, 14, 1055-1056.	3.9	1
67	Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism. <i>Medicine (United States)</i> , 2015, 94, e1118.	1.0	1
68	Reply: Is cognition key in paradoxical kinesia?. <i>Movement Disorders</i> , 2011, 26, 365-365.	3.9	0